Dr. Matthew P Deek, MD
Claim this profileRutgers Cancer Institute of New Jersey
Studies Cancer
Studies Tumors
5 reported clinical trials
10 drugs studied
Area of expertise
1Cancer
Stage IV
Stage I
Stage II
2Tumors
Stage IV
Affiliated Hospitals
Clinical Trials Matthew P Deek, MD is currently running
Triapine + Targeted Radiation
for Neuroendocrine Cancer
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
Recruiting1 award Phase 2
High-Dose Radiation
for Bone Metastases Pain
The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated biologically equivalent dose (BED) will result in a higher proportion of participants responding to treatment, and will also lead to more durable responses. Furthermore, the investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 35-45% in painful non-bone metastases
Recruiting1 award Phase 211 criteria
More about Matthew P Deek, MD
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Matthew P Deek, MD has experience with
- EXTERNAL BEAM RADIATION
- AN0025
- Fluorouracil
- Capecitabine
- Mitomycin
- Intensity-Modulated Radiation Therapy
Breakdown of trials Matthew P Deek, MD has run
Cancer
Lung Cancer
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew P Deek, MD specialize in?
Matthew P Deek, MD focuses on Cancer and Tumors. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage I.
Is Matthew P Deek, MD currently recruiting for clinical trials?
Yes, Matthew P Deek, MD is currently recruiting for 4 clinical trials in New Brunswick New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Matthew P Deek, MD has studied deeply?
Yes, Matthew P Deek, MD has studied treatments such as EXTERNAL BEAM RADIATION, AN0025, Fluorouracil.
What is the best way to schedule an appointment with Matthew P Deek, MD?
Apply for one of the trials that Matthew P Deek, MD is conducting.
What is the office address of Matthew P Deek, MD?
The office of Matthew P Deek, MD is located at: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903 United States. This is the address for their practice at the Rutgers Cancer Institute of New Jersey.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.